Leonard Lim, MD
Pulmonary Disease · Greenwood, SCNPI 1104106368
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 567 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.
Across 567 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Sanofi$973
- Boehringer Ingelheim$825
- United Therapeutics Corporation$777
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$1501%
- Food & beverage$10,67996%
- Education$2732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 90 | $1,646 |
| GSK | 108 | $1,535 |
| Actelion Pharmaceuticals US, Inc. | 59 | $1,339 |
| Sanofi | 35 | $973 |
| Boehringer Ingelheim | 50 | $825 |
| United Therapeutics Corporation | 35 | $777 |
| Mylan Specialty L.p. | 24 | $425 |
| Gilead | 18 | $409 |
| Merck | 16 | $368 |
| Insmed, Inc. | 16 | $315 |
| Verona Pharma, Inc. | 19 | $307 |
| Amgen | 12 | $227 |
| Regeneron Healthcare Solutions, Inc. | 9 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $181 |
| Genentech USA, Inc. | 9 | $181 |
| Grifols USA, LLC | 9 | $167 |
| Hill-rom Company, Inc | 1 | $150 |
| Harmony Biosciences LLC | 4 | $103 |
| ANI Pharmaceuticals, Inc. | 5 | $101 |
| Baxter Healthcare | 3 | $100 |
| Sunovion Pharmaceuticals Inc. | 5 | $92 |
| Bayer | 3 | $82 |
| Electromed, Inc. | 5 | $79 |
| Intuitive Surgical | 1 | $78 |
| Advanced Respiratory, Inc | 3 | $55 |
| Viatris Specialty LLC | 2 | $52 |
| Circassia Inc. | 3 | $50 |
| Mallinckrodt Enterprises LLC | 2 | $44 |
| Shire North American Group Inc | 2 | $42 |
| Veran Medical Technologies, Inc. | 3 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Liquidia Technologies, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Pfizer | 1 | $17 |
| Medtronic | 1 | $15 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,102 in reported general payments places this provider in the 75th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 15 | $372,682 |
| OfevNintedanib Esylate | 27 | $291,211 |
| OpsumitMacitentan | 22 | $274,002 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 225 | $172,153 |
| Dupixent PenDupilumab | 21 | $81,762 |
| Ambrisentan | 11 | $77,302 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $42,493 |
| Tadalafil | 37 | $34,823 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $28,011 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $24,821 |
| Spiriva RespimatTiotropium Bromide | 23 | $14,128 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 25 | $12,816 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $7,326 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $6,923 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 221 | $6,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $825 | $312,26265 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,339 | $274,00222 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,535 | $232,311360 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,646 | $60,597103 claims |
| MerckBelsomra | $368 | $4,99812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Greenwood
- John Patrick TejadaGreenwood$16K
- Raymond LewisGreenwood$10K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.